Zabinski R A, Vance-Bryan K, Krinke A J, Walker K J, Moody J A, Rotschafer J C
Miles Inc., West Haven, Connecticut 06516-4175.
Antimicrob Agents Chemother. 1993 Nov;37(11):2454-8. doi: 10.1128/AAC.37.11.2454.
An in vitro pharmacodynamic system has been successfully adapted to simulate in vivo antimicrobial pharmacokinetics under anaerobic conditions. This system was used to perform time-kill kinetic studies which were designed to compare the activity of temafloxacin to ciprofloxacin and cefotetan against two strains of Bacteroides fragilis (ATCC 25285 and ATCC 23745). All experiments were performed as single-dose, 24-h, duplicate runs. Starting bacterial inocula of 10(7) CFU/ml were exposed to starting antimicrobial concentrations of 5 micrograms of temafloxacin per ml, 5 micrograms of ciprofloxacin per ml, and 100 micrograms of cefotetan per ml. Terminal half-lives of 8, 4, and 4 h were simulated for each antimicrobial agent. Temafloxacin was rapidly bactericidal against B. fragilis. Ciprofloxacin was not bactericidal (< 3 log10 unit decline in bacterial numbers) to either strain of B. fragilis. Cefotetan was bactericidal (> or = 3 log10 unit decline in bacterial numbers) to each strain but killed at a slower rate than temafloxacin. Times to 3 log10 unit declines of strain ATCC 25285 were 2, 4, and > 24 h, whereas those of strain ATCC 23745 were 4, 4, and > 24 h for temafloxacin, cefotetan, and ciprofloxacin, respectively. Total logarithmic declines of strain ATCC 25285 were > 4.5, > 4.5, and 2.9 log10 CFU/ml, whereas those of strain ATCC 23745 were 4.1, > 4.5, and 1.2 log10 CFU/ml for each drug, respectively. These and other studies demonstrated that temafloxacin showed potential as an agent that could have been further developed for use in the treatment of anaerobic infections. However, the drug was removed from the market by its manufacturer because of toxicity issues. Although the release of newer fluoroquinolones that possess significant activity against anaerobic bacteria does not appear imminent, the time-kill studies performed in this study demonstrate that further research is warranted in the development of fluoroquinolones which possess significant antianaerobic activity.
一种体外药效学系统已成功适用于模拟厌氧条件下的体内抗菌药代动力学。该系统用于进行时间-杀菌动力学研究,旨在比较替马沙星与环丙沙星和头孢替坦对两株脆弱拟杆菌(ATCC 25285和ATCC 23745)的活性。所有实验均以单剂量、24小时、重复运行的方式进行。起始细菌接种量为10(7) CFU/ml,暴露于起始抗菌浓度为每毫升5微克替马沙星、每毫升5微克环丙沙星和每毫升100微克头孢替坦的环境中。模拟每种抗菌药物的终末半衰期分别为8、4和4小时。替马沙星对脆弱拟杆菌具有快速杀菌作用。环丙沙星对任何一株脆弱拟杆菌均无杀菌作用(细菌数量下降<3个对数10单位)。头孢替坦对各菌株均有杀菌作用(细菌数量下降≥3个对数10单位),但杀菌速度比替马沙星慢。对于ATCC 25285菌株,达到3个对数10单位下降的时间分别为2、4和>24小时,而对于ATCC 23745菌株,替马沙星、头孢替坦和环丙沙星达到该下降幅度的时间分别为4、4和>24小时。ATCC 25285菌株的总对数下降分别大于4.5、大于4.5和2.9个对数10 CFU/ml,而ATCC 23745菌株的总对数下降分别为4.1、大于4.5和1.2个对数10 CFU/ml。这些研究及其他研究表明,替马沙星显示出作为一种可进一步开发用于治疗厌氧感染的药物的潜力。然而,由于毒性问题,该药物被其制造商撤出市场。尽管具有显著抗厌氧菌活性的新型氟喹诺酮类药物的推出似乎并不迫在眉睫,但本研究中进行的时间-杀菌研究表明,在开发具有显著抗厌氧活性的氟喹诺酮类药物方面仍有必要进行进一步研究。